Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Cell Mol Biol (Noisy-le-grand) ; 70(5): 204-208, 2024 May 27.
Article in English | MEDLINE | ID: mdl-38814215

ABSTRACT

Parkinson's disease (PD) remains the most common neurodegenerative disease worldwide, seriously affecting the normal life of patients. Currently, there is no effective clinical cure for PD. In this study, the research team explored the effect of ketamine (KET) on PD, which can lay a reliable foundation for future KET treatment of PD. First, the research team established a PD rat model with 6-hydroxydopamine (6-OHDA). The detection showed that the maximum angle of the inclined plate stay, the number of times of grid crossings and standing, and the ATPase activity in brain tissue were significantly lower in PD rats than in control rats, while the positive rate of α-synuclein in brain tissue was increased, showing typical pathological manifestations of PD. After using KET to intervene in PD rats, the behavioral and brain pathological changes were significantly alleviated, and the inflammation and oxidative stress damage of brain tissue were effectively reduced, suggesting the potential therapeutic effects of KET on PD. Furthermore, the use of KET inhibited the PI3K/AKT axis in the brain tissue of PD rats and promoted autophagy. Moreover, the significant suppression of the PI3K/AKT axis by KET was also demonstrated in the PD cell model established through lipopolysaccharide (LPS) inducement of astrocyte cell line HA1800. It is suggested that the mechanism of KET on PD is related to the inhibition of the PI3K/AKT axis.


Subject(s)
Astrocytes , Ketamine , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Rats, Sprague-Dawley , Signal Transduction , Animals , Ketamine/pharmacology , Ketamine/therapeutic use , Phosphatidylinositol 3-Kinases/metabolism , Astrocytes/drug effects , Astrocytes/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Male , Rats , Autophagy/drug effects , Oxidative Stress/drug effects , Parkinson Disease/drug therapy , Parkinson Disease/metabolism , Parkinson Disease/pathology , Brain/drug effects , Brain/metabolism , Brain/pathology , Disease Models, Animal , Oxidopamine , Lipopolysaccharides , Humans
2.
Nat Protoc ; 16(11): 5193-5219, 2021 11.
Article in English | MEDLINE | ID: mdl-34697467

ABSTRACT

Application of synthetic nucleoside analogues to capture newly transcribed RNAs has unveiled key features of RNA metabolism. Whether this approach could be adapted to isolate the RNA-bound proteome (RNA interactome) was, however, unexplored. We have developed a new method (capture of the newly transcribed RNA interactome using click chemistry, or RICK) for the systematic identification of RNA-binding proteins based on the incorporation of 5-ethynyluridine into newly transcribed RNAs followed by UV cross-linking and click chemistry-mediated biotinylation. The RNA-protein adducts are then isolated by affinity capture using streptavidin-coated beads. Through high-throughput RNA sequencing and mass spectrometry, the RNAs and proteins can be elucidated globally. A typical RICK experimental procedure takes only 1 d, excluding the steps of cell preparation, 5-ethynyluridine labeling, validation (silver staining, western blotting, quantitative reverse-transcription PCR (qRT-PCR) or RNA sequencing (RNA-seq)) and proteomics. Major advantages of RICK are the capture of RNA-binding proteins interacting with any type of RNA and, particularly, the ability to discern between newly transcribed and steady-state RNAs through controlled labeling. Thanks to its versatility, RICK will facilitate the characterization of the total and newly transcribed RNA interactome in different cell types and conditions.


Subject(s)
Click Chemistry , RNA , HeLa Cells , High-Throughput Nucleotide Sequencing , Humans , Proteomics , Sequence Analysis, RNA
SELECTION OF CITATIONS
SEARCH DETAIL